Clinical trial
BATTLE Program: Erlotinib in Previously Treated Subjects With Advanced NSCLC
NCT00410059 · M.D. Anderson Cancer Center, Other · Completed
Key facts
| NCT number | NCT00410059 |
|---|---|
| Title | BATTLE Program: Erlotinib in Previously Treated Subjects With Advanced NSCLC |
| Official title | A Phase II, Open Label Study of Erlotinib (Tarceva) in Previously Treated Subjects With Advanced Non-Small Cell Lung Cancer |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Collaborators | United States Department of Defense U.S. Fed |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lung Cancer |
| Intervention type | Drug |
| Interventions | Erlotinib |
| Enrollment | 59 |
| Start date | Nov 1, 2006 |
| Primary completion | Jul 1, 2016 |
| Completion | Jul 1, 2016 |
| First posted | Dec 12, 2006 |
| Last update posted | Aug 2, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: